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Abstract
Context: Individuals differ in their sensitivity to drug treatment, including that
with muscarinic receptor antagonists used in the treatment of overactive bladder
(OAB), due to a combination of pharmacodynamic and pharmacokinetic reasons.
Objective: To discuss the variability in drug response among individual patients,
the concept of the dose-response curve, and the selection of drug dosage as well as
how these factors are integrated when optimising OAB treatment using the
muscarinic receptor antagonist fesoterodine as an example.
Evidence acquisition: Data sources were identiﬁed in 2010 using a nonsystematic
search and included articles and abstracts selected using expert opinion of their
relevance to drug response in OAB.
Evidence synthesis: A given drug dose is unlikely to yield the same quantitative
response in all patients, and undertreatment (too little efﬁcacy) or overtreatment
(too many side effects) may occur. The position and shape of the dose-response
curve for a drug may differ between patients and within a patient for desired and
adverse effects. The availability of two or more drug doses allows for titration
(ﬂexible dosing) to ﬁnd the dose exhibiting the optimal clinical efﬁcacy that is
tolerable for an individual patient. Optimally, a patient would have symptom
resolution with no adverse events (AEs). Realistically, an efﬁcacy-to-tolerability
ratio (therapeutic index) exists for each of the combinations of selected efﬁcacy
metrics and AE reports.
Conclusions: Dose titration is important for selection of an effective dose of a
treatment with minimal side effects.
# 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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Overactive bladder syndrome (OAB) is a prevalent condition
with an adverse impact on the quality of life of the affected
patients and their partners [1]. Muscarinic receptor
antagonists are the mainstay of pharmacologic OAB
treatment [2]. Although effective for many patients, the
use of antimuscarinics can be associated with adverse1569-9056/$ – see front matter# 2011 European Association of Urology. Publisevents (AEs) such as dry mouth or constipation [2]. Of note,
on initial observation, patients may appear to have either a
limited response to standard doses of antimuscarinics (low
efficacy and low AEs) or may be sensitive to antimuscarinic
agents (high efficacy, possibly accompanied by high AEs).
On more careful inspection, there are multiple permuta-
tions of response because the individual dose-response
curves for the selected efficacy metrics and the observedhed by Elsevier B.V. All rights reserved. doi:10.1016/j.eursup.2011.01.004
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individual clinical responses. The clinical extremes are the
patient who attains full resolution of OAB symptoms with
no AEs and the patient who experiences intolerable AEs
with no clinical response. The clinical ideal is a dosage range
that allows a trade-off between efficacy and tolerability and
provides the option inmost patients to titrate to the desired
level of either or both. Therefore, it is necessary to find the
optimal treatment for each individual patient, and drugs
that provide individual dose titration are advantageous in
such situations. Against this background, we will summa-
rise multiple potential factors that may be involved in
interindividual differences in antimuscarinic sensitivity,
relate these to the concept of the dose-response curve, and
illustrate these scenarios with the muscarinic receptor
antagonist fesoterodine, an agent used in OAB treatment.
2. Evidence acquisition
Data sources were identified in 2010 using a nonsystematic
search of Medline (using the generic names of muscarinic
antagonists used in OAB treatment as search terms), 2008–
2010 abstract volumes of major urology journals, and
standard pharmacology textbooks. From this search,
articles and abstracts were selected by their relevance to
drug response in OAB.
3. Evidence synthesis
3.1. Interindividual differences in sensitivity to antimuscarinics
The quantitative response to a drug, such as a muscarinic
antagonist, can vary between patients due to a combination
of pharmacodynamic (PD) and pharmacokinetic (PK)
factors. Pharmacodynamics describes what a drug does to
the organism, whereas pharmacokinetics describes what the
organism does with the drug, mostly the processes of
absorption, distribution, metabolism, and elimination
(ADME).
Reasons for PD variability between patients include
alterations of receptor expression due to age or concomitant
disease [3] or based on genotype [4]. Concomitant medica-
tions that act on muscarinic receptors may also contribute
to PD variability [5]. PD causes of differential response
typically apply to all members of a drug class acting on a
given molecular target (eg, a muscarinic receptor).
PK causes of response variability between patients,
either in the entire body or in individual compartments,
relate to exposure to different drug concentrations on
ingestion of the same dose. They can have their effects at all
stages of pharmacokinetics (ie, ADME). At the absorption
level, this can involve interactionswith food, for example, as
demonstrated for some a1-adrenoceptor antagonists [6]. At
the distribution level, binding to plasma proteins [7] or
penetration through the blood–brain barrier (BBB) [8] can
contribute to variability of drug response in the entire body
or specific compartments. Variability at the level of drug
metabolism can occur from hepatic impairment or may bebased on genetic polymorphisms of drug-metabolising
enzymes, particularly CYP 2D6 [9], or by induction or
inhibition of these enzymes by concomitant medication
[10]. At the excretion level, differences in renal function
may contribute to drug exposure, particularly for drugs that
are excreted largely by the kidneys [11]. In contrast to PD
causes of differential drug response, PK causes are not
necessarily shared by all members of a drug class but rather
relate to the specific chemical properties of a given drug
and, for this reason, can differ between compounds within a
drug class [12].
In clinical practice, many if not most of the PD and PK
factors contributing to interindividual differences in
sensitivity to antimuscarinics are unknown for an individ-
ual patient. This means that treatments must be tried for
the patient to find a specific drug and dose that serves the
patientwith a personally optimised efficacy-to-tolerability
ratio.
3.2. The concept of the dose-response curve
Finding the right dose for a given patient is not only a
question of efficacy but rather of the efficacy-to-tolerability
ratio. This is important because AEs are a major reason for
patient dissatisfaction and discontinuation of treatment
[13]. Both desired effects and AEs exhibit specific dose-
response curves that are not necessarily the same (Fig. 1). It
is possible, for example, that a drug target may be
differentially regulated in tissues mediating desired effects
and AEs [14]. Additionally, the underlying PK reasons for
differential drug exposure may not have the same result in
each body compartment, for example, due to distribution
barriers such as the BBB. A differential dose-response curve
for desired effects and AEs is the basis for functional
‘‘uroselectivity’’ [15].
To understand this, it is necessary to take a closer look at
the principles behind a dose-response curve. There are two
types of dose-response curve. In most cases, dose-response
curves are graded (ie, with increasing dose, the effect
increases). This can relate to a dose-dependent improve-
ment of OAB symptoms but also to the intensity of an AE
such as the intensity of dry mouth with muscarinic
antagonists. Additionally, examples exist where an increas-
ing dose is not associatedwith a greater response but with a
more likely response (eg, a greater likelihood of any dry
mouth with a greater drug dose). For simplicity, we will
primarily focus on graded drug responses in this manu-
script, but the same principles are also applicable to
nongraded responses with some minor modifications.
A given drug dose yields a given exposure to this drug for
a given patient at a specific point in time. Changes in
exposure at the very low end or the very high end of the
dose-response curve have only a small effect on the
response (Fig. 1). In contrast, if exposure is close to
the middle part of the dose-response curve, changes in
drug dose can have major effects on response. This can be
seen as the ‘‘sweet spot’’ of the dose-response curve, where
a response can be titrated to the desired level (assuming
sufficient dosing options are available). Unfortunately, we
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Fig. 1 – A hypothetical dose-response curve for a uroselective drug.
Responses for the desired effect are shown in green, and those for
adverse effects are shown with orange dots. Both curves have been
normalised for maximum responses.
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Fig. 2 – Effects of dose escalation on a hypothetical dose-response curve
for a uroselective drug. (A) Escalation from a dose yielding low exposure
increases efficacy while maintaining or even improving the efficacy-to-
tolerability ratio. (B) Escalation from a dose yielding high exposure has
limited effect on efficacy and worsens the efficacy-to-tolerability ratio.
Responses for the desired effect are shown in green, and those for
adverse effects are shown with orange dots. Both curves have been
normalised for maximum responses.
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below or above it andmust make assumptions based on the
observed efficacy-to-tolerability profile. Typically, the dose-
ranging phase 2 studies, as part of clinical drug develop-
ment, attempt to define a dose aiming for this spot at the
group level.
If a patient with a low drug exposure is escalated to a
higher dose, there is typically a gain in efficacy that is
similar to or larger than the increase in AEs; thus, the overall
efficacy-to-tolerability ratio increases or at least is main-
tained (Fig. 2a). In contrast, a patient already having a high
drug exposure (ie, already above the sweet spot) and
escalated to a higher dose is likely to experience only a
limited gain in efficacy because the effect may already be
close to the maximum (ceiling) effect. In such a patient, the
AEs may increase substantially, leading to worsening of the
efficacy-to-tolerability ratio (Fig. 2b).
The concept of treatment optimisation by dose escala-
tion is well established in some therapeutic areas, such as in
the treatment of arterial hypertension [16], but apparently
it is not effective for other conditions, such as the use of
selective serotonin reuptake inhibitors in the treatment of
depression [17]. Hence a well-documented dose-response
curve is important, so we know that an increased dose will
lead to greater drug exposure and therapeutic response.
This heterogeneity between therapeutic areas necessitates
exploration of the situation specifically for the use of
muscarinic antagonists used in OAB treatment.
3.3. Dose-escalation of muscarinic antagonists
If we have difficulty predicting whether a given dose in a
given patient is already in the low, middle, or high part of
the dose-response curve, the previously noted concept has
practical consequences. However, conclusions for an
individual patient need to be based on group averages.
Within a cohort of patients receiving a given dose of a
muscarinic antagonist, some will have high drug sensitivityfor PD and/or PK reasons. In these patients, a low drug dose
will already have considerable efficacy. If these patients are
escalated to a higher dose, they are unlikely to see
substantial additional improvement of efficacy but may
experience more AEs, leading to an overall worsened
efficacy-to-tolerability ratio and possibly to discontinuation
of treatment. Starting at the lowest available dosewill allow
identification of those patients who are sensitive respond-
ers. In contrast, there will also be patients with low drug
sensitivity, that is, thosewith reduced tissue responsiveness
due to PD reasons and/or those reaching only low exposure
with that dose for PK reasons. In most cases, they will lack
not only sufficient benefit but also relevant AEs at the low
dose. These patients will experience only an insufficient
treatment response at a low drug dose and hence are
candidates for dose escalation. Without the opportunity for
dose escalation, they may discontinue treatment due to a
lack of efficacy. However, if they are escalated to a higher
dose, they may have a better treatment response while still
having acceptable tolerability.
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starting OAB treatment at a low dose and escalating to a
higher dosewhen needed. However, some physicians prefer
to start patients on a high dose and ‘‘de-escalate’’ if
bothersome AEs are noted. This is done with the idea of
giving the patient positive reinforcement secondary to rapid
symptom reduction, but it risks losing some patients due to
AEs. In a chronic and non-life-threatening condition such as
OAB, we prefer the approach of a low starting dose, also
recommended in the package insert. This can be thought of
in terms of the Hippocratic principle of non nocere (‘‘do no
harm’’) to avoid unnecessary AEs.
3.4. The fesoterodine example of a dose-response curve
Tolterodine is a well established antimuscarinic drug that
delivers two types of active moiety: the parent compound
itself and its active metabolite, 5-hydroxymethyl tolter-
odine (5-HMT) [18]. Because formation of 5-HMT from
tolterodine is mediated by CYP 2D6 and 5-HMT exhibits
smaller BBB penetration than the parent compound
tolterodine [8], subjects with a genetically low activity of
CYP 2D6 (‘‘poor metabolisers’’) are more likely to experi-
ence central nervous system AEs such as rapid eye
movement sleep disturbances than those with normal
enzyme activity [19]. Moreover, this PK variability in
tolterodine exposure creates a risk of a dose that is too
high in some patients and has been a reason why the drug
was developed clinically at the dose of only 4 mg/d [18].
Fesoterodine is an antimuscarinic that is rapidly and
completely metabolised to 5-HMT independently of CYP
2D6 [20]. Although 5-HMT itself can be further metabolised
and hence inactivated by both CYP 2D6 and 3A4, it can be[()TD$FIG]Placebo
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Fig. 3 – Modelling of the dose-response curve of fesoterodine: effects on micturi
data from two phase 2 and two phase 3 studies. Reproduced with permissionexpected that overall exposure to the active drug moiety
exhibits less variability with fesoterodine than with
tolterodine, and indirect comparison between studies with
both drugs confirm this assumption [20]. Moreover, such
reduced variability in exposure to active antimuscarinic
moiety has recently been demonstrated in a direct
comparative PK study of fesoterodine and tolterodine
[21]. This more predictable exposure has allowed the
development of fesoterodine in 4-mg and 8-mg doses for
additional flexibility, providing dosing suitable for a wider
range of patients.
The PK profile of fesoterodine has been well established.
It exhibits a dose-proportional drug exposure that is largely
independent of concomitant food intake and is suitable for
once-daily dosing [22,23]. The pharmacokinetics of fesoter-
odine are largely independent of age, race, and gender [24]
or of whether the drug is taken in the morning or evening
[25]. Whereas the elimination of 5-HMT involves metabo-
lism and renal excretion, only modest increases in 5-HMT
exposures were observed in patients with renal [26] or
hepatic impairment [27].
In combination, the noted PK factors are responsible for
relatively small variability in 5-HMT exposure with
fesoterodine treatment [20,21] and may contribute to a
well-defined clinical dose-response curve. This was evident
in a post hoc analysis of the pooled data from the two phase
3 studies; 8 mg of fesoterodine had a significantly greater
effect on all diary variables except micturition frequency, as
compared with 4 mg of fesoterodine [28]. Data from the
dose-ranging phase 2 studies are also compatible with this
idea [29,30]. In a flexible-dose, open-label study, about 50%
of all patients opted for an increase to the 8-mg dose at
week 4 [31]. In a placebo-controlled flexible-dose study,Fesoterodine 4 mg
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from BioMed Central [34].
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Fig. 4 – Modelling of the dose-response curve of fesoterodine: effects on urgency urinary incontinence episode frequency in the treatment of overactive
bladder, based on the pooled data from two phase 2 and two phase 3 studies. Reproduced with permission from BioMed Central [34].
E U RO P E AN URO L OGY S U P P L EMEN T S 1 0 ( 2 0 1 1 ) 8 – 1 31263% of patients opted for a dose increase to 8 mg at week 2
[32]. The overall data have allowed modelling of responses
to various fesoterodine doses (Fig. 3 and 4). These data
suggest that individual optimisation of treatment along
the dose-response curve can improve treatment outcomes
(ie, the efficacy-to-tolerability ratio). Recent studies with
other muscarinic receptor antagonists further support this
concept [33].
4. Conclusions
Dose titration is important for selection of an effective dose
of a treatment with minimal side effects. Individual patient
characteristics, dose-response efficacy-to-tolerability rela-
tionships, and individual drug characteristics will deter-
mine not only the response to the lower dose but also the
relative efficacy and tolerability index improvement with
dose escalation. Flexible dosing allows patients to choose a
dose based on desire for efficacy (without or with
tolerability issues) or based on tolerability (with or without
maximum efficacy) relative to the dose-response curves for
that individual. The characteristics of a drug and the dosage
options will determine where individuals start on the
efficacy and tolerability curves and the subsequent position
on these curves after escalation.
Reliable dose-response curves are needed for the results
of titration to be predictable. Fesoterodine has been
designed to provide a clear dose-response relationship for
OAB treatment, and extensive PK studies have validated this
approach. The available clinical data from both fixed- and
flexible-dose studies support this idea.Conflicts of interest
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